Top

Published in:

01-10-2016 | Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (C Shay and B Conway, Section Editors)

Viral Hepatitis and Diabetes: Clinical Implications of Diabetes Prevention Through Hepatitis Vaccination

Authors: Rudruidee Karnchanasorn, Horng-Yih Ou, James Lin, Lee-Ming Chuang, Ken C. Chiu

Published in: Current Diabetes Reports | Issue 10/2016

Abstract

Viral hepatitis has been posited to play a role in the development of type 2 diabetes. Thus, prevention of viral hepatitis through vaccination has the potential to reduce the burden of type 2 diabetes. We have shown that successful hepatitis B vaccination reduces the risk of diabetes by 33 %. Although diabetes can be prevented by behavior modification and pharmaceutical agents, these require significant personal commitment and cost. In contrast, diabetes prevention through hepatitis B vaccination would require little personal commitment and relatively low cost. In this review, we discuss hepatitis viruses A, B, and C and their interaction with diabetes; explore the potential underlying mechanisms and potential for hepatitis vaccination to reduce diabetes; and estimate the medical expense savings that would result from such an intervention. Given the projected increase of diabetes prevalence in the developing regions, where hepatitis B is endemic, exploration of such an intervention is very timely.

DeFronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–95. doi:10.2337/db09-9028.CrossRefPubMedPubMedCentral

Cherrington AD. Banting lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes. 1999;48:1198–214.CrossRefPubMed

Bergman RN. Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia. 2000;43:946–52.CrossRefPubMed

Chap Z, Ishida T, Chou J, Hartley CJ, Entman ML, Brandenburg D, et al. First-pass hepatic extraction and metabolic effects of insulin and insulin analogues. Am J Physiol. 1987;252:E209–17.PubMed

Ader M, Bergman RN. Peripheral effects of insulin dominate suppression of fasting hepatic glucose production. Am J Physiol. 1990;258(6 Pt 1):E1020–32.PubMed

Magnusson I, Rothman DL, Katz LD, Shulman RG, Shulman GI. Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. J Clin Invest. 1992;90:1323–7.CrossRefPubMedPubMedCentral

DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 1989;38:387–95.CrossRefPubMed

Roden M, Petersen KF, Shulman GI. Nuclear magnetic resonance studies of hepatic glucose metabolism in humans. Recent Prog Horm Res. 2001;56:219–37.CrossRefPubMed

Moore MC, Smith MS, Sinha VP, Beals JM, Michael MD, Jacober SJ, et al. Novel PEGylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes. 2014;63:494–504. doi:10.2337/db13-0826.CrossRefPubMed

10.

Gregory JM, Kraft G, Scott MF, Neal DW, Farmer B, Smith MS, et al. Insulin delivery into the peripheral circulation: a key contributor to hypoglycemia in type 1 diabetes. Diabetes. 2015;64:3439–51. doi:10.2337/db15-0071.CrossRefPubMed

11.

Picardi A, D’Avola D, Gentilucci UV, Galati G, Fiori E, Spataro S, et al. Diabetes in chronic liver disease: from old concepts to new evidence. Diabetes Metab Res Rev. 2006;22:274–83.CrossRefPubMed

12.

Moscatiello S, Manini R, Marchesini G. Diabetes and liver disease: an ominous association. Nutr Metab Cardiovasc Dis. 2007;17:63–70.CrossRefPubMed

13.

Petrides AS, DeFronzo RA. Glucose and insulin metabolism in cirrhosis. J Hepatol. 1989;8:107–14.CrossRefPubMed

14.

Merli M, Leonetti F, Riggio O, Valeriano V, Ribaudo MC, Strati F, et al. Glucose intolerance and insulin resistance in cirrhosis are normalized after liver transplantation. Hepatology. 1999;30:649–54.CrossRefPubMed

15.

Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28:637–53. doi:10.1016/j.bpg.2014.07.008.CrossRefPubMed

16.

Yki-Jarvinen H. Nutritional modulation of non-alcoholic fatty liver disease and insulin resistance. Nutrients. 2015;7:9127–38. doi:10.3390/nu7115454.CrossRefPubMedPubMedCentral

17.

Firneisz G. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol. 2014;20:9072–89. doi:10.3748/wjg.v20.i27.9072.PubMedPubMedCentral

18.

Huang J, Karnchanasorn R, Ou HY, Feng W, Chuang LM, Chiu KC, et al. Association of insulin resistance with serum ferritin and aminotransferases-iron hypothesis. World J Exp Med. 2015;5:232–43. doi:10.5493/wjem.v5.i4.232.CrossRefPubMedPubMedCentral

19.

Facchini FS, Hua NW, Stoohs RA. Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology. 2002;122:931–9.CrossRefPubMed

20.

Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes. 2002;51:1000–4.CrossRefPubMed

21.•

Mohlke KL, Boehnke M. Recent advances in understanding the genetic architecture of type 2 diabetes. Hum Mol Genet. 2015;24:R85–92. doi:10.1093/hmg/ddv264. This article provides the complex insight of genetics of type 2 diabetes.CrossRefPubMed

22.

Kahn R, Davidson MB. The reality of type 2 diabetes prevention. Diabetes Care. 2014;37:943–9. doi:10.2337/dc13-1954.CrossRefPubMedPubMedCentral

23.

Fernandez-Real JM, Pickup JC. Innate immunity, insulin resistance and type 2 diabetes. Trends Endocrinol Metab. 2008;19:10–6.CrossRefPubMed

24.•

Huang J, Ou HY, Lin J, Karnchanasorn R, Feng W, Samoa R, et al. The impact of hepatitis B vaccination status on the risk of diabetes, implicating diabetes risk reduction by successful vaccination. PLoS One. 2015;10(10):e0139730. doi:10.1371/journal.pone.0139730. This article provides the first evidence that diabetes could be prevented from hepatitis B vaccination.CrossRefPubMedPubMedCentral

25.•

Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;386(9995):743–800. doi:10.1016/j.diabres.2013.11.002. This article provides the detailed epidemiological information on viral hepatitis and diabetes.CrossRef

26.

Jacobsen KH, Wiersma ST. Hepatitis a virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010;28:6653–7.CrossRefPubMed

27.

Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010;14:1–21.CrossRefPubMed

28.

Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–67.CrossRefPubMed

29.

Viral hepatitis. 2016. http://www.cdc.gov/hepatitis/ Accessed on April 1, 2016

30.

Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599–607. doi:10.1056/NEJMoa1512610.CrossRefPubMed

31.

Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med. 2015;373:2608–17. doi:10.1056/NEJMoa1512612.CrossRefPubMed

32.

Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98. doi:10.1056/NEJMoa1402454.CrossRefPubMed

33.•

National Academies of Sciences, Engineering, and Medicine. Eliminating the public health problem of hepatitis B and C in the United States. Washington, DC: National Academies Press, April 11, 2016. https://www.nationalacademies.org/hmd/Reports/2016/Eliminating-the-Public-Health-Problem-of-Hepatitis-B-and-C-in-the-US.aspx. This book provides the detailed information on both hepatitis B and C.

34.

Buckley GJ, Strom BL. What stands in the way of making hepatitis B and C rare diseases in the United States? Ann Intern Med. 2016. doi:10.7326/M16-0772.PubMed

35.

Hwang YC, Jeong IK, Chon S, Oh S, Ahn KJ, Chung HY, et al. Fulminant type 1 diabetes mellitus associated with acute hepatitis A. Diabet Med. 2010;27:366–7. doi:10.1111/j.1464-5491.2010.02930.x.CrossRefPubMed

36.

Atabek ME, Kart H, Erkul I. Prevalence of hepatitis A, B, C and E virus in adolescents with type-1 diabetes mellitus. Int J Adolesc Med Health. 2003;15:133–7.CrossRefPubMed

37.

Vesely DL, Dilley RW, Duckworth WC, Paustian FF. Hepatitis A-induced diabetes mellitus, acute renal failure, and liver failure. Am J Med Sci. 1999;317:419–24.CrossRefPubMed

38.

Lutsey PL, Pankow JS, Bertoni AG, Szklo M, Folsom AR. Serological evidence of infections and type 2 diabetes: the Multiethnic Study of Atherosclerosis. Diabet Med. 2009;26:149–52. doi:10.1111/j.1464-5491.2008.02632.x.CrossRefPubMedPubMedCentral

39.

Oli JM, Nwokolo C. Diabetes after infectious hepatitis: a follow-up study. Br Med J. 1979;7;1(6168):926–7.CrossRef

40.

Chupin M, Charbonnel B, Le BL, Grolleau JY, Chupin F, Guillon J. Glucose tolerance in viral hepatitis. A study of twenty patients during the acute phase and after recovery. Diabetes. 1978;27:661–9.CrossRefPubMed

41.

Adi FC. Diabetes mellitus associated with epidemic of infectious hepatitis in Nigeria. Br Med J. 1974;1(5900):183–5.CrossRefPubMedPubMedCentral

42.

Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol. 2001;35:279–83.CrossRefPubMed

43.

Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Goglia F, et al. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care. 2005;28:2548–50.CrossRefPubMed

44.

Huang JF, Dai CY, Hwang SJ, Ho CK, Hsiao PJ, Hsieh MY, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol. 2007;102:1237–43.CrossRefPubMed

45.

Arao M, Murase K, Kusakabe A, Yoshioka K, Fukuzawa Y, Ishikawa T, et al. Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. J Gastroenterol. 2003;38:355–60.CrossRefPubMed

46.

Imazeki F, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int. 2008;28(3):355–62.CrossRefPubMed

47.

Wang CS, Wang ST, Yao WJ, Chang TT, Chou P. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol. 2007;166(2):196–203.CrossRefPubMed

48.

Papatheodoridis GV, Chrysanthos N, Savvas S, Sevastianos V, Kafiri G, Petraki K, et al. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepat. 2006;13(5):303–10.CrossRefPubMed

49.

Spradling PR, Simons B, Narayanan M, Xing J, Homan C, Bulkow L, et al. Incidence of diabetes mellitus in a population-based cohort of persons with chronic hepatitis B virus infection. J Viral Hepat. 2013;20(7):510–3.CrossRefPubMed

50.

Huang ZS, Huang TS, Wu TH, Chen MF, Hsu CS, Kao JH. Asymptomatic chronic hepatitis B virus infection does not increase the risk of diabetes mellitus: a ten-year observation. J Gastroenterol Hepatol. 2010;25(8):1420–5.CrossRefPubMed

51.

Khalili M, Lombardero M, Chung RT, Terrault NA, Ghany MG, Kim WR, et al. Diabetes and prediabetes in patients with hepatitis B residing in North America. Hepatology. 2015;62(5):1364–74.CrossRefPubMed

52.

Zhang J, Shen Y, Cai H, Liu YM, Qin G. Hepatitis B virus infection status and risk of type 2 diabetes mellitus: a meta-analysis. Hepatol Res. 2015;45(11):1100–9.CrossRefPubMed

53.

Eslam M, Khattab MA, Harrison SA. Insulin resistance and hepatitis C: an evolving story. Gut. 2011;60(8):1139–51.CrossRefPubMed

54.

Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. [comment in: Ann intern Med. 2000 Oct 17;133(8):650-1]. Ann Intern Med. 2000;133(8):592–9.CrossRefPubMed

55.

Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology. 2003;38(1):50–6.CrossRefPubMed

56.

Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: myth or reality? Dig Liver Dis. 2016;48(2):105–11.CrossRefPubMed

57.

White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49(5):831–44.CrossRefPubMedPubMedCentral

58.

Naing C, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol. 2012;18(14):1642–51.CrossRefPubMedPubMedCentral

59.

Simo R, Lecube A, Genesca J, Esteban JI, Hernandez C. Sustained virological response correlates with reduction in the incidence of glucose abnormalities in patients with chronic hepatitis C virus infection. Diabetes Care. 2006;29(11):2462–6.CrossRefPubMed

60.

Garcia-Compean D, Gonzalez-Gonzalez JA, Lavalle-Gonzalez FJ, Gonzalez-Moreno EI, Villarreal-Perez JZ, Maldonado-Garza HJ. Current concepts in diabetes mellitus and chronic liver disease: clinical outcomes, hepatitis C virus association, and therapy. Dig Dis Sci. 2015;13.

61.

Dyal HK, Aguilar M, Bartos G, Holt EW, Bhuket T, Liu B, et al. Diabetes mellitus increases risk of hepatocellular carcinoma in chronic hepatitis C virus patients: a systematic review. Dig Dis Sci. 2016;61(2):636–45.CrossRefPubMed

62.

Giordanino C, Bugianesi E, Smedile A, Ciancio A, Abate ML, Olivero A, et al. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. Am J Gastroenterol. 2008;103(10):2481–7.CrossRefPubMed

63.

Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3):734–43.CrossRefPubMed

64.

Ruhl CE, Menke A, Cowie CC, Everhart JE. Relationship of hepatitis C virus infection with diabetes in the U.S. population. Hepatology. 2014;60(4):1139–49.CrossRefPubMedPubMedCentral

65.

Stepanova M, Lam B, Younossi Y, Srishord MK, Younossi ZM. Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity. J Viral Hepat. 2012;19(5):341–5.CrossRefPubMed

66.

Donadon V, Balbi M, Mas MD, Casarin P, Zanette G. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int. 2010;30(5):750–8.CrossRefPubMed

67.

Roome AJ, Walsh SJ, Cartter ML, Hadler JL. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA. 1993;270(24):2931–4.CrossRefPubMed

68.

Wong VC, Ip HM, Reesink HW, Lelie PN, Reerink-Brongers EE, Yeung CY, et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study. Lancet. 1984;1(8383):921–6.CrossRefPubMed

69.

Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis A, Gerin JL, Purcell RH. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology. 1987;92(6):1844–50.CrossRefPubMed

70.

Reddy MB, Clark L. Iron, oxidative stress, and disease risk. Nutrition Rev. 2004;62(3):120–4.CrossRef

71.

Tuomainen TP, Diczfalusy U, Kaikkonen J, Nyyssonen K, Salonen JT. Serum ferritin concentration is associated with plasma levels of cholesterol oxidation products in man. Free Radic Biol Med. 2003;35(8):922–8.CrossRefPubMed

72.

Wang XH, Cheng PP, Jiang F, Jiao XY. The effect of hepatitis B virus infection on hepcidin expression in hepatitis B patients. Ann Clin Lab Sci. 2013;43(2):126–34.PubMed

73.

Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: specific detection of negative-strand viral RNA in various tissues. Hepatology. 1998;28(5):1398–401.CrossRefPubMed

74.

Masini M, Campani D, Boggi U, Menicagli M, Funel N, Pollera M, et al. Hepatitis C virus infection and human pancreatic beta-cell dysfunction. Diabetes Care. 2005;28(4):940–1.CrossRefPubMed

75.

Lecube A, Hernandez C, Genesca J, Simo R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: a case-control study. Diabetes Care. 2006;29(5):1096–101.CrossRefPubMed

76.

Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–49.CrossRefPubMed

77.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047–53.CrossRefPubMed

78.

Zhuo X, Zhang P, Barker L, Albright A, Thompson TJ, Gregg E. The lifetime cost of diabetes and its implications for diabetes prevention. Diabetes Care. 2014;37(9):2557–64.CrossRefPubMed

Title: Viral Hepatitis and Diabetes: Clinical Implications of Diabetes Prevention Through Hepatitis Vaccination
Authors: Rudruidee Karnchanasorn
Horng-Yih Ou
James Lin
Lee-Ming Chuang
Ken C. Chiu
Publication date: 01-10-2016
Publisher: Springer US
Published in: Current Diabetes Reports / Issue 10/2016
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-016-0790-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 10/2016

Salivary Amylase: Digestion and Metabolic Syndrome

Diet and Gut Microbial Function in Metabolic and Cardiovascular Disease Risk

Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis

What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?

SGLT2 Inhibitors: Benefit/Risk Balance

Taking Telemedicine to the Next Level in Diabetes Population Management: a Review of the Endo ECHO Model

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage